Celularity is developing off-the-shelf, placental-derived allogeneic cell therapies, including mesenchymal-like adherent stromal cells and engineered T-cells, to provide scalable treatment options for aging-related diseases, cancer, and immune disorders. By utilizing the readily available postpartum placenta, Celularity addresses the need for effective and accessible cellular therapies in the healthcare market.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many aging-related diseases, cancers, and immune disorders lack scalable and readily available treatment options. Traditional approaches to cellular therapies face challenges in terms of cell sourcing, manufacturing scalability, and cost-effectiveness. This creates a significant unmet need for accessible and affordable therapies.
Solution
Celularity develops off-the-shelf, allogeneic cell therapies derived from the postpartum placenta to address a range of diseases. These therapies include mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. By leveraging the unique biology and readily available source material of the placenta, Celularity aims to provide scalable, high-quality cellular medicines. Their integrated manufacturing and research center facilitates the development and production of these advanced therapies, targeting unmet needs in aging-related diseases, cancer, and immune disorders.
Target Audience
The primary target audience includes patients suffering from aging-related diseases, cancer, and immune disorders, as well as healthcare providers seeking scalable and accessible cellular therapy options.
Features
- Allogeneic, cryopreserved cell therapies derived from postpartum placenta
- Mesenchymal-like adherent stromal cells (MLASCs) for regenerative medicine applications
- CAR T-cell therapies for targeted cancer treatment
- Genetically modified and unmodified natural killer (NK) cells for immune modulation
- Purpose-built, fully integrated manufacturing and research facility
- GMP-capable suites for clinical-scale production
- Advanced biomaterial product line